Thank You and Notification of Publication Ending

We would like to thank you for your loyal readership over the last 12.5 years. We have enjoyed providing you with oncology and hematology clinical updates, conference coverage, and regulatory approval updates.

However, the prIME LINES team would like to inform you that prIME LINES will cease publication at the end of April 2020. Our last clinical post was made on April 17 and our last email newsletter will go out on April 30. However, we will keep the prIME LINES webpage up through July 1, 2020, should you wish to access previous articles.

We sincerely hope that you have found our publication useful in the daily care of your patients with cancer.

And we would like to thank Bojana Pajk, MD, MSc, Chelsey Goins, PhD, and the many others that were involved in curating the content and building the newsletter over the past decade.

You can continue to access timely oncology and hematology clinical updates, conference coverage, and regulatory updates at Medscape Oncology and access CME-certified educational activities and conference coverage at Medscape Education Oncology.

Sincerely,
The prIMELINES Team

Clinical Opinion Poll

When would you recommend dabrafenib + trametinib combo for a patient with advanced, symptomatic, PD-L1–low, lung adenocarcinoma and BRAF V600 mutation?